China Pharma Holdings (CPHI) Revenue (2010 - 2026)

China Pharma Holdings (CPHI) has reported Revenue for 17 consecutive years, with $948340.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 7.55% year-over-year to $948340.0; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (down 10.97% YoY), and the FY2025 full-year result was $4.1 million, down 8.49% from the prior year.
• Revenue slipped to $948340.0 in Q2 2026 per CPHI's latest filing, from $983536.0 in the prior quarter.
• Across five years, Revenue topped out at $2.9 million in Q4 2022 and bottomed at $756217.0 in Q3 2025.
• Historically, Revenue has averaged $1.4 million across 5 years, with a median of $1.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Revenue grew 22.21% in 2023, then slumped 47.25% in 2024.
• Over 5 years, Revenue stood at $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then sank by 47.25% to $1.1 million in 2024, then grew by 8.11% to $1.2 million in 2025, then retreated by 22.65% to $948340.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $948340.0, $983536.0, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.